Verve Therapeutics (VERV) Competitors $5.73 -0.06 (-1.04%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VERV vs. HRMY, KNSA, MIRM, ARVN, WVE, NRIX, RXRX, OCUL, NAMS, and TECXShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Mirum Pharmaceuticals (MIRM), Arvinas (ARVN), Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), NewAmsterdam Pharma (NAMS), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Harmony Biosciences Kiniksa Pharmaceuticals Mirum Pharmaceuticals Arvinas Wave Life Sciences Nurix Therapeutics Recursion Pharmaceuticals Ocular Therapeutix NewAmsterdam Pharma Tectonic Therapeutic Verve Therapeutics (NASDAQ:VERV) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Do analysts recommend VERV or HRMY? Verve Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 349.83%. Harmony Biosciences has a consensus price target of $47.00, suggesting a potential upside of 43.95%. Given Verve Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verve Therapeutics is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Harmony Biosciences 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the media favor VERV or HRMY? In the previous week, Harmony Biosciences had 18 more articles in the media than Verve Therapeutics. MarketBeat recorded 32 mentions for Harmony Biosciences and 14 mentions for Verve Therapeutics. Harmony Biosciences' average media sentiment score of 0.85 beat Verve Therapeutics' score of 0.34 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verve Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 12 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VERV or HRMY more profitable? Harmony Biosciences has a net margin of 17.53% compared to Verve Therapeutics' net margin of -933.08%. Harmony Biosciences' return on equity of 22.97% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-933.08% -35.20% -27.54% Harmony Biosciences 17.53%22.97%13.96% Do insiders & institutionals believe in VERV or HRMY? 97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, VERV or HRMY? Harmony Biosciences has higher revenue and earnings than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$20.65M23.44-$200.07M-$2.59-2.21Harmony Biosciences$656.11M2.86$128.85M$1.9516.91 Does the MarketBeat Community prefer VERV or HRMY? Harmony Biosciences received 32 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 66.25% of users gave Harmony Biosciences an outperform vote while only 50.00% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformVerve TherapeuticsOutperform Votes2150.00% Underperform Votes2150.00% Harmony BiosciencesOutperform Votes5366.25% Underperform Votes2733.75% Which has more volatility and risk, VERV or HRMY? Verve Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. SummaryHarmony Biosciences beats Verve Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Porter & CompanyThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.06M$7.14B$5.37B$8.40BDividend YieldN/A8.77%5.21%4.20%P/E Ratio-2.2116.47140.7317.73Price / Sales23.44254.681,437.0778.19Price / CashN/A50.1638.9433.56Price / Book0.785.684.744.59Net Income-$200.07M$151.16M$115.38M$225.45M7 Day PerformanceN/A-1.43%-0.60%-0.22%1 Month Performance18.18%6.29%3.92%1.93%1 Year Performance-52.49%40.64%39.36%33.41% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics2.1094 of 5 stars$5.73-1.0%$26.00+353.8%-38.5%$484.90M$20.65M-2.21110Upcoming EarningsHRMYHarmony Biosciences4.8984 of 5 stars$34.05flat$44.38+30.3%+71.5%$1.93B$656.11M17.46200Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownKNSAKiniksa Pharmaceuticals2.6195 of 5 stars$26.92+0.3%$33.60+24.8%+46.7%$1.91B$338.93M-168.24220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMIRMMirum Pharmaceuticals4.6843 of 5 stars$39.36+2.4%$56.82+44.4%+43.8%$1.86B$264.38M-17.19140Upcoming EarningsNews CoveragePositive NewsARVNArvinas2.2793 of 5 stars$26.94+1.6%$57.69+114.2%+83.4%$1.84B$93.30M-5.21445Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap DownWVEWave Life Sciences4.9621 of 5 stars$14.82+1.0%$19.44+31.2%+163.7%$1.82B$110.50M-26.00240Analyst ForecastNRIXNurix Therapeutics1.5958 of 5 stars$25.22+1.8%$29.40+16.6%+357.6%$1.81B$76.99M-8.67300RXRXRecursion Pharmaceuticals2.8722 of 5 stars$6.36+0.5%$9.40+47.8%+25.8%$1.79B$44.58M-3.93400Upcoming EarningsOCULOcular Therapeutix4.2742 of 5 stars$10.89+0.3%$16.57+52.2%+348.6%$1.76B$58.44M-8.07267Upcoming EarningsShort Interest ↓NAMSNewAmsterdam Pharma3.2983 of 5 stars$18.86-2.3%$33.80+79.2%+151.0%$1.70B$7.42M0.0057Upcoming EarningsShort Interest ↑TECXTectonic Therapeutic3.4746 of 5 stars$36.40+5.5%$60.00+64.8%N/A$1.63BN/A-7.04120 Related Companies and Tools Related Companies Harmony Biosciences Competitors Kiniksa Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arvinas Competitors Wave Life Sciences Competitors Nurix Therapeutics Competitors Recursion Pharmaceuticals Competitors Ocular Therapeutix Competitors NewAmsterdam Pharma Competitors Tectonic Therapeutic Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VERV) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.